Qingying Huakang Secures Strategic Investment from Yimai Sunshine to Advance AI-Driven Consumer-Focused Medical Imaging Solutions

Beijing Qingying Huakang Technology Co., Ltd. (“Qingying Huakang”), an innovative provider of medical imaging solutions, recently signed a strategic investment agreement with Jiangxi Yimai Yangguang Group Co., Ltd. (“Yimai Yangguang”). The proceeds from this round of investment will primarily be allocated to two areas: first, developing product models and forms that are more consumer-oriented; and second, exploring the implementation of advanced consumer-facing medical imaging solutions.

Qingying Huakang was incubated by the Biomedical Imaging Research Center at Tsinghua University, focusing on the development of innovative medical imaging solutions. Its founder, Dr. Li Rui, is a researcher at Tsinghua University’s Biomedical Imaging Center. Leveraging nearly 30 years of expertise in technology development, pathological validation, clinical trials, and data accumulation in this field, Dr. Li’s team co-founded Qingying Huakang with industry experts in 2016. The company translates scientific achievements from Tsinghua University’s Biomedical Imaging Research Center into commercial products, providing high-resolution magnetic resonance imaging (MRI) solutions for the diagnosis and treatment of cerebrovascular diseases.

Currently, Qingying Huakang has integrated professional imaging sequences, high signal-to-noise ratio (SNR) imaging coils, artificial intelligence interpretation algorithms, and imaging workstations into a one-stop solution ranging from image acquisition to report generation, thereby making clinical applications more standardized and efficient. In terms of market sales, the company has adopted a "product + service" sales model targeting clinicians and patients with cerebrovascular diseases. The annual market size for the product is RMB 640 million, while the market capacity for services amounts to RMB 58 billion. The company has obtained two medical device registration certificates, achieved sales in over 100 hospitals, and built a team of more than 30 professionals dedicated to product R&D and marketing. Recognized as a Zhongguancun High-Tech Enterprise and a National High-Tech Enterprise, the company has completed Series A financing at the ten-million-yuan level.

Dr. Li Rui, Founder of the CompanyIntroduction: Artificial intelligence, particularly deep learning technology, has brought about profound transformations across many industries. The big data nature of medical imaging and its visual observational characteristics have made AI applications feasible. However, amidst the hype in the investment and financing market, we observe significant challenges in the practical implementation of AI in medical imaging. The main reasons can be analyzed as follows: First, AI lacks diverse application scenarios. Currently, most medical imaging AI companies address routine clinical tasks, merely helping to reduce costs and improve efficiency without creating new growth points. Second, AI lacks a viable reimbursement model. In the absence of supportive policies and inclusion in official fee schedules, charging for AI services in hospitals remains largely theoretical. Third, AI lacks adequate industry regulation. Although some companies have obtained medical device registration certificates for their AI products, ethical issues and questions regarding liability, rights, and responsibilities persist in AI applications. Qingying Huakang views AI primarily as a powerful tool, guided by clinical needs, and applies it across various aspects including signal acquisition, image reconstruction, image analysis, and clinical decision-making, thereby forming an end-to-end solution package. This approach creates new implementation scenarios. The strategic cooperation with Yimai Yangguang aims to further advance AI adoption by leveraging the application scenarios offered by third-party imaging centers.

Regarding the strategic cooperation between both parties,Dr. Li Feiyu, Vice President of Yimai YangguangHe stated, “What we value in our partnership with Qingying Huakang is, on the one hand, the advanced nature of its one-stop, end-to-end medical imaging solution built upon the research foundations of Tsinghua University and the University of Washington; on the other hand, Yimai Yangguang operates nearly 100 imaging centers, and as its scale expands, the shortage of specialized imaging technical talent at the grassroots level has become increasingly prominent. AI technology can help compensate for this lack of professional personnel at the primary care level. Over the past two years, Yimai Yangguang and the Medical Biological Imaging Center of Tsinghua University have engaged in comprehensive, in-depth exchanges and reached a strategic cooperation consensus. Moving forward, Yimai Yangguang will collaborate with Qingying Huakang to further advance the development of products such as identification of vulnerable atherosclerotic plaques and prediction of intracranial aneurysm rupture risk in the field of cardiovascular and cerebrovascular health, thereby laying a solid foundation for providing distinctive imaging services.”

The collaboration between Yimai Yangguang and Qingying Huakang will foster robust upstream-downstream synergy, enabling active exploration and experimentation in the consumer-facing general health market. Dr. Li Feiyu stated, “Compared with hospital patients, individuals undergoing health checkups have distinct characteristics, with a higher proportion being healthy or sub-healthy. As society develops and public attention to personal health status increases, this proportion is expected to continue rising. The demand for radiation-free, non-invasive, efficient, and rapid imaging examinations is more pronounced among the health-checkup population. Magnetic resonance imaging (MRI) is the optimal imaging modality for extensive, radiation-free, and non-invasive vascular examinations, making it well-suited for large-scale screening. We look forward to jointly creating a new ecosystem for medical imaging through our combined efforts.”

Yimai Yangguang was invested in and established in 2014 by a group of elites from China’s medical imaging industry. It is an imaging hospital group specializing in the investment and operation of medical imaging centers, the development of medical imaging cloud platform technologies, the training of medical imaging professionals, and services across the medical imaging industry chain. As a pioneer and leader among third-party medical imaging centers in China, Yimai Yangguang has always centered on “medical imaging services,” adhering to technological and business model innovation. By developing its three core business pillars—physician groups, medical imaging cloud services, and the Medical Imaging Academy—it aims to build a comprehensive service platform covering the entire medical imaging industry chain, thereby serving the whole medical imaging sector.

Yimai Yangguang is dedicated to the construction and operation of medical imaging centers, medical imaging empowerment solutions, and the application and development of imaging big data. In the future, Yimai Yangguang will remain committed to “medical imaging services” as its core, uphold technological and business model innovation, and build China’s largest and most advanced full-industry-chain service platform for medical imaging, thereby leading the development of China’s medical imaging industry.

Leveraging our strong market development capabilities, superior operational management expertise, a comprehensive network of imaging physicians along with robust training systems, and systematic data cloud services, we have pioneered a leading regional shared-service model. By integrating the provincial general manager responsibility system with the city partner framework, alongside a refined project management system and risk control mechanisms, we are executing a four-step strategy: expanding territories and establishing centers, deepening operational excellence through meticulous management, achieving leapfrog growth via data services, and building platforms empowered by ecosystem collaboration. Through this approach, we are progressively realizing our corporate vision of “building China’s—and indeed the world’s—largest and most influential specialized imaging hospital, and constructing a premier medical imaging service platform.”